Abemaciclib
S66466
Phase 2 small_molecule active
Quick answer
Abemaciclib for Triple Negative Breast Neoplasms is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Triple Negative Breast Neoplasms
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active